Adlai Nortye (ANL) Stock Analysis

What Adlai Nortye does

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.

Key metrics

ETFs linked to ANL

Broad-market and Healthcare sector ETFs an investor holding Adlai Nortye is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ANL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Adlai Nortye?

Adlai Nortye trades under the ticker ANL on NASDAQ.

Which exchange is ANL listed on?

ANL is listed on NASDAQ.

What sector does Adlai Nortye operate in?

Adlai Nortye is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ANL in a portfolio?

PortView shows ANL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.